FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288062282> ?p ?o ?g. }

• W4288062282 endingPage "1759720X2211139" @default.
• W4288062282 startingPage "1759720X2211139" @default.
• W4288062282 abstract "Several studies have reported that the use of chondroitin sulphate (CS) and glucosamine may reduce the risk of acute myocardial infarction. Although it is thought that this potential benefit could be extended to ischaemic stroke (IS), the evidence is scarce.To test the hypothesis that the use of prescription glucosamine or CS reduces the risk of IS.Case-control study nested in an open cohort.Patients aged 40-99 years registered in a Spanish primary healthcare database (BIFAP) during the 2002-2015 study period. From this cohort, we identified incident cases of IS, applying a case-finding algorithm and specific validation procedures, and randomly sampled five controls per case, individually matched with cases by exact age, gender and index date. Adjusted odds ratios (AORs) and 95% confidence interval (CI) were computed through a conditional logistic regression. Only new users of glucosamine or CS were considered.A total of 13,952 incident cases of IS and 69,199 controls were included. Of them, 106 cases (0.76%) and 803 controls (1.16%) were current users of glucosamine or CS at index date, yielding an AOR of 0.66 (95% CI: 0.54-0.82) (for glucosamine, AOR: 0.55; 95% CI: 0.39-0.77; and for CS, AOR: 0.77; 95% CI: 0.60-0.99). The reduced risk among current users was observed in both sexes (men, AOR: 0.69; 95% CI: 0.49-0.98; women, AOR: 0.65; 95% CI: 0.50-0.85), in individuals above and below 70 years of age (AOR: 0.69; 95% CI: 0.53-0.89 and AOR: 0.59; 95% CI: 0.41-0.85, respectively), in individuals with vascular risk factors (AOR: 0.53; 95% CI: 0.39-0.74) and among current/recent users of nonsteroidal anti-inflammatory drugs (NSAIDs) (AOR: 0.71; 95% CI: 0.55-0.92). Regarding duration, the reduced risk was observed in short-term users (<365 days, AOR: 0.61; 95% CI: 0.48-0.78) while faded and became nonsignificant in long-term users (>364 days AOR: 0.86; 95% CI: 0.57-1.31).Our results support a protective effect of prescription CS and glucosamine in IS, which was observed even in patients at vascular risk.Our aim was to analyse whether the use of glucosamine or chondroitin sulphate (CS) reduces the risk of ischaemic stroke (IS). We detected a significant decrease." @default.
• W4288062282 created "2022-07-28" @default.
• W4288062282 creator A5002251871 @default.
• W4288062282 creator A5008912002 @default.
• W4288062282 creator A5012387973 @default.
• W4288062282 creator A5012578644 @default.
• W4288062282 creator A5022056494 @default.
• W4288062282 creator A5032115647 @default.
• W4288062282 creator A5040712332 @default.
• W4288062282 creator A5052403823 @default.
• W4288062282 creator A5060832273 @default.
• W4288062282 creator A5061681102 @default.
• W4288062282 creator A5071164705 @default.
• W4288062282 creator A5081760822 @default.
• W4288062282 creator A5085904915 @default.
• W4288062282 creator A5088294114 @default.
• W4288062282 date "2022-01-01" @default.
• W4288062282 modified "2023-09-30" @default.
• W4288062282 title "Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case–control study" @default.
• W4288062282 cites W1519596698 @default.
• W4288062282 cites W1600041372 @default.
• W4288062282 cites W1677834975 @default.
• W4288062282 cites W1737800200 @default.
• W4288062282 cites W1900801758 @default.
• W4288062282 cites W1918652666 @default.
• W4288062282 cites W1919216911 @default.
• W4288062282 cites W1971127969 @default.
• W4288062282 cites W1983702729 @default.
• W4288062282 cites W1986908357 @default.
• W4288062282 cites W2020116183 @default.
• W4288062282 cites W2027020554 @default.
• W4288062282 cites W2029609892 @default.
• W4288062282 cites W2053360847 @default.
• W4288062282 cites W2054191814 @default.
• W4288062282 cites W2083666488 @default.
• W4288062282 cites W2089330181 @default.
• W4288062282 cites W2093195995 @default.
• W4288062282 cites W2099329307 @default.
• W4288062282 cites W2115805053 @default.
• W4288062282 cites W2118278569 @default.
• W4288062282 cites W2121383038 @default.
• W4288062282 cites W2122717603 @default.
• W4288062282 cites W2123105952 @default.
• W4288062282 cites W2126149568 @default.
• W4288062282 cites W2130513475 @default.
• W4288062282 cites W2131796098 @default.
• W4288062282 cites W2149696055 @default.
• W4288062282 cites W2152252241 @default.
• W4288062282 cites W2157583343 @default.
• W4288062282 cites W2161739351 @default.
• W4288062282 cites W2161823701 @default.
• W4288062282 cites W2164595809 @default.
• W4288062282 cites W2167362639 @default.
• W4288062282 cites W2275737843 @default.
• W4288062282 cites W2285253591 @default.
• W4288062282 cites W2471469740 @default.
• W4288062282 cites W2804302886 @default.
• W4288062282 cites W2806600767 @default.
• W4288062282 cites W2914327061 @default.
• W4288062282 cites W2946400128 @default.
• W4288062282 cites W3015024056 @default.
• W4288062282 cites W3036829854 @default.
• W4288062282 cites W3100034845 @default.
• W4288062282 cites W3180131846 @default.
• W4288062282 cites W335966889 @default.
• W4288062282 doi "https://doi.org/10.1177/1759720x221113937" @default.
• W4288062282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35923649" @default.
• W4288062282 hasPublicationYear "2022" @default.
• W4288062282 type Work @default.
• W4288062282 citedByCount "0" @default.
• W4288062282 crossrefType "journal-article" @default.
• W4288062282 hasAuthorship W4288062282A5002251871 @default.
• W4288062282 hasAuthorship W4288062282A5008912002 @default.
• W4288062282 hasAuthorship W4288062282A5012387973 @default.
• W4288062282 hasAuthorship W4288062282A5012578644 @default.
• W4288062282 hasAuthorship W4288062282A5022056494 @default.
• W4288062282 hasAuthorship W4288062282A5032115647 @default.
• W4288062282 hasAuthorship W4288062282A5040712332 @default.
• W4288062282 hasAuthorship W4288062282A5052403823 @default.
• W4288062282 hasAuthorship W4288062282A5060832273 @default.
• W4288062282 hasAuthorship W4288062282A5061681102 @default.
• W4288062282 hasAuthorship W4288062282A5071164705 @default.
• W4288062282 hasAuthorship W4288062282A5081760822 @default.
• W4288062282 hasAuthorship W4288062282A5085904915 @default.
• W4288062282 hasAuthorship W4288062282A5088294114 @default.
• W4288062282 hasBestOaLocation W42880622821 @default.
• W4288062282 hasConcept C126322002 @default.
• W4288062282 hasConcept C127413603 @default.
• W4288062282 hasConcept C146304588 @default.
• W4288062282 hasConcept C151956035 @default.
• W4288062282 hasConcept C156957248 @default.
• W4288062282 hasConcept C165617652 @default.
• W4288062282 hasConcept C178790620 @default.
• W4288062282 hasConcept C185592680 @default.
• W4288062282 hasConcept C187212893 @default.
• W4288062282 hasConcept C201903717 @default.
• W4288062282 hasConcept C2778125326 @default.
• W4288062282 hasConcept C2780645631 @default.

• next